spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Rentschler Biotechnologie GmbH Announces Transition into a European Corporation Called Rentschler Biopharma SE

Rentschler Biotechnologie GmbH

Rentschler Biotechnologie GmbH announced that the Company has successfully transitioned into a European corporation (SE) with entry into the German commercial register on October 1, 2017

Laupheim, Germany, October 4, 2017 – Rentschler Biotechnologie GmbH, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that the Company has successfully transitioned into a European corporation (SE) with entry into the German commercial register on October 1, 2017. The Company is operating as Rentschler Biopharma SE with immediate effect. There will be no operational changes for clients or employees of the family-owned company due to the transition.

“With our transition to Rentschler Biopharma SE, we emphasize our long-term international corporate identity, while the core business remains unaffected. In future, this legal form of company strengthens our position as a full-service CDMO and ensures our place as a leader in this industry,” commented Prof. Dr. Nikolaus F. Rentschler, Owner of Rentschler Biopharma SE. “Our proven service offering along the entire value chain – from bioprocess development through biomanufacturing to fill and finish of biopharmaceuticals – remains unchanged. This also applies to our company sites and manufacturing facilities as well as the existing client relations and importantly their contact persons.”

Over the recent years, Rentschler Biopharma has grown considerably and invested constantly in facilities so that capacities have more than doubled. With the expansion of our facilities, a continually growing number of employees has also been added to the Company. About 200 employees have been recruited in all business segments during the past year and a half. In the current fiscal year, over 120 additional positions are to be filled.

Rentschler will present itself as Rentschler Biopharma SE for the first time at the 23rd Annual International Partnering Conference BIO-Europe at booth 42/43. The conference takes place November 6-8, 2017 at Messe Berlin.

The term “European Corporation”, from the Latin: Societas Europaea (SE), is a legal form for incorporated companies in the European Union and the European Economic Area and enables the foundation of companies according to standardized legal principles.

About Rentschler Biopharma SE
Rentschler Biopharma SE, located in Laupheim, Germany, is a leading contract development and manufacturing organization (CDMO) for bioprocess development and manufacturing of biopharmaceuticals as well as for related consulting activities in terms of project management and regulatory support. The Company's clients include innovative biotech companies and major pharmaceutical companies around the world. Many years of experience and excellence in finding solutions as well as certified quality management and advanced technologies ensure Rentschler Biopharma's high quality standards. Rentschler Biopharma is a family-owned company employing approximately 750 people. For further information, please visit www.rentschler-biopharma.com.

Contact
Rentschler Biopharma SE
Dr. Marion Schrader
Senior Director Company Communication and Public Relations marion.schrader@rentschler-biopharma.com
phone +49 7392 701-0
email info@rentschler.de
web www.rentschler.de
email Erwin-Rentschler-Str. 21, 88471 Laupheim
 
Print this page
Send to a friend
   
spacer
News and Press Releases

York Health Economics Consortium offers an updated training event

Health economics evidence is a key element in much health services research and particularly in health technology assessments, including submissions for NICE single technology appraisals. Identifying economic evidence to inform submissions involves searches in a range of databases and uses a variety of strategies.
More info >>


White Papers

Case Study: Molly™ Auto Injector

SHL Group

The Molly™ Auto Injector is a revolutionary, ultra-compact device, designed for convenience and portability. With the handling process reduced to only 2 simple steps— uncap and inject — Molly™ is incredibly intuitive to use, and quickly became a new benchmark for the auto injector industry. In addition to the many enhanced features that benefit patients, Molly™ was also uniquely designed to offer an alternative business model for customers, one that allowed them to minimize initial investments while maximizing speed-to-market.
More info >>

Industry Events

LogiPharma Europe 2018

10-12 April 2018, Montreux Music & Convention Centre

Now in it’s 18th successful year, LogiPharma is the largest global end-to-end supply chain event for pharma supply chain leaders, their teams and service partners.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement